These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15119916)

  • 1. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone.
    Nasrallah HA; Duchesne I; Mehnert A; Janagap C; Eerdekens M
    J Clin Psychiatry; 2004 Apr; 65(4):531-6. PubMed ID: 15119916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
    Kane JM; Eerdekens M; Lindenmayer JP; Keith SJ; Lesem M; Karcher K
    Am J Psychiatry; 2003 Jun; 160(6):1125-32. PubMed ID: 12777271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
    Fleischhacker WW; Eerdekens M; Karcher K; Remington G; Llorca PM; Chrzanowski W; Martin S; Gefvert O
    J Clin Psychiatry; 2003 Oct; 64(10):1250-7. PubMed ID: 14658976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study.
    Isitt JJ; Nadipelli VR; Kouassi A; Fava M; Heidbreder C
    Schizophr Res; 2016 Jul; 174(1-3):126-131. PubMed ID: 27066860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting risperidone: a review of its use in schizophrenia.
    Harrison TS; Goa KL
    CNS Drugs; 2004; 18(2):113-32. PubMed ID: 14728058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.
    Simpson GM; Mahmoud RA; Lasser RA; Kujawa M; Bossie CA; Turkoz I; Rodriguez S; Gharabawi GM
    J Clin Psychiatry; 2006 Aug; 67(8):1194-203. PubMed ID: 16965196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
    Lindenmayer JP; Khan A
    Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone.
    Gharabawi GM; Lasser RA; Bossie CA; Zhu Y; Amador X
    Int Clin Psychopharmacol; 2006 Jul; 21(4):233-40. PubMed ID: 16687995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.
    Taylor DM; Young CL; Mace S; Patel MX
    J Clin Psychiatry; 2004 Aug; 65(8):1076-83. PubMed ID: 15323592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
    J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical review of a long-acting, injectable formulation of risperidone.
    Knox ED; Stimmel GL
    Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder.
    Ciliberto N; Bossie CA; Urioste R; Lasser RA
    Int Clin Psychopharmacol; 2005 Jul; 20(4):207-12. PubMed ID: 15933481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.